Literature DB >> 8195389

Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans.

J S Youngner1, J J Treanor, R F Betts, P Whitaker-Dowling.   

Abstract

On the basis of the ability of the attenuated cold-adapted strain of influenza A virus to suppress disease production in ferrets simultaneously infected with epidemic influenza virus (P. Whitaker-Dowling, H.F. Maassab, and J.S. Youngner, J. Infect. Dis. 164:1200-1202, 1991), an evaluation of the ability of the cold-adapted virus to modify clinical disease in humans was made. Adult volunteers with prechallenge serum hemagglutination-inhibition titers to the influenza A/Kawasaki/86 (H1N1) virus of < or = 1:8 received either 10(7) 50% tissue culture infective doses of the wild-type A/Kawasaki virus or a mixture of 10(7) 50% tissue culture infective doses of each of the wild-type virus and a cold-adapted A/Kawasaki reassortant virus by intranasal drops in a randomized, double-blind fashion. Symptoms and wild-type virus shedding were assessed daily for 6 days following challenge. Results were compared with those derived from another group of volunteers who received only cold-adapted virus. Volunteers who received the mixed inoculum of cold-adapted and wild-type viruses had lower symptom scores than those who received wild-type virus alone, suggesting that coinfection with the cold-adapted virus may modify wild-type virus infection, but the differences were not statistically significant in this small study. The data demonstrate that administration of cold-adapted influenza A virus to humans at the time of wild-type virus infection is a safe procedure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8195389      PMCID: PMC263119          DOI: 10.1128/jcm.32.3.750-754.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Adaptation and growth characteristics of influenza virus at 25 degrees c.

Authors:  H F Maassab
Journal:  Nature       Date:  1967-02-11       Impact factor: 49.962

2.  Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines.

Authors:  M H Snyder; R F Betts; D DeBorde; E L Tierney; M L Clements; D Herrington; S D Sears; R Dolin; H F Maassab; B R Murphy
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

3.  Dose response of cold-adapted, reassortant influenza A/California/10/78 virus (H1N1) in adult volunteers.

Authors:  B R Murphy; M L Clements; H P Madore; J Steinberg; S O'Donnell; R Betts; D Demico; R C Reichman; R Dolin; H F Maassab
Journal:  J Infect Dis       Date:  1984-05       Impact factor: 5.226

4.  Evaluation of a cold-recombinant influenza virus vaccine in ferrets.

Authors:  H F Maassab; A P Kendal; G D Abrams; A S Monto
Journal:  J Infect Dis       Date:  1982-12       Impact factor: 5.226

5.  Attenuation of wild-type human influenza A virus by acquisition of the PA polymerase and matrix protein genes of influenza A/Ann Arbor/6/60 cold-adapted donor virus.

Authors:  M H Snyder; M L Clements; D De Borde; H F Maassab; B R Murphy
Journal:  J Clin Microbiol       Date:  1985-11       Impact factor: 5.948

6.  Dominant-negative mutants as antiviral agents: simultaneous infection with the cold-adapted live-virus vaccine for influenza A protects ferrets from disease produced by wild-type influenza A.

Authors:  P Whitaker-Dowling; H F Maassab; J S Youngner
Journal:  J Infect Dis       Date:  1991-12       Impact factor: 5.226

7.  Laboratory-based surveillance of influenza A(H1N1) and A(H3N2) viruses in 1980-81: antigenic and genomic analyses.

Authors:  N J Cox; Z S Bai; A P Kendal
Journal:  Bull World Health Organ       Date:  1983       Impact factor: 9.408

8.  The genes associated with trans-dominance of the influenza A cold-adapted live virus vaccine.

Authors:  P Whitaker-Dowling; R Zvolenski; J S Youngner
Journal:  Virology       Date:  1991-01       Impact factor: 3.616

9.  Cold-adapted vaccine strains of influenza A virus act as dominant negative mutants in mixed infections with wild-type influenza A virus.

Authors:  P Whitaker-Dowling; W Lucas; J S Youngner
Journal:  Virology       Date:  1990-04       Impact factor: 3.616

10.  Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers.

Authors:  B R Murphy; M B Rennels; R G Douglas; R F Betts; R B Couch; T R Cate; R M Chanock; A P Kendal; H F Maassab; S Suwanagool; S B Sotman; L A Cisneros; W C Anthony; D R Nalin; M M Levine
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

  10 in total
  11 in total

Review 1.  The threat of avian influenza A (H5N1). Part IV: Development of vaccines.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-06-01       Impact factor: 3.402

Review 2.  The potential for a controlled human infection platform in Singapore.

Authors:  Shobana Balasingam; Peter Horby; Annelies Wilder-Smith
Journal:  Singapore Med J       Date:  2014-09       Impact factor: 1.858

3.  Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.

Authors:  Pedro A Piedra; Manjusha J Gaglani; Mark Riggs; Gayla Herschler; Charles Fewlass; Matt Watts; Claudia Kozinetz; Colin Hessel; W Paul Glezen
Journal:  Pediatrics       Date:  2005-09       Impact factor: 7.124

4.  Immunomodulatory properties of subcellular fractions of a G+ bacterium, Bacillus firmus.

Authors:  Dana Cechova; Michaela Novakova; Karel Mikulik; Olga Novotna; Jaroslav Julak; Peter Zanvit; Ludmila Prokesova
Journal:  Folia Microbiol (Praha)       Date:  2012-08-09       Impact factor: 2.099

5.  Heterosubtypic immunity to influenza A virus infection requires a properly diversified antibody repertoire.

Authors:  Huan H Nguyen; Michael Zemlin; Ivaylo I Ivanov; Judit Andrasi; Cosima Zemlin; Huong L Vu; Robert Schelonka; Harry W Schroeder; Jiri Mestecky
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

6.  Exposure of hepatitis C virus (HCV) RNA-positive recipients to HCV RNA-positive blood donors results in rapid predominance of a single donor strain and exclusion and/or suppression of the recipient strain.

Authors:  T Laskus; L F Wang; M Radkowski; H Vargas; M Nowicki; J Wilkinson; J Rakela
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.

Authors:  Rob Lambkin-Williams; Colin Gelder; Richard Broughton; Corey P Mallett; Anthony S Gilbert; Alex Mann; David He; John S Oxford; David Burt
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

Review 8.  The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.

Authors:  Rob Lambkin-Williams; Nicolas Noulin; Alex Mann; Andrew Catchpole; Anthony S Gilbert
Journal:  Respir Res       Date:  2018-06-22

9.  Multi-scale modeling for the transmission of influenza and the evaluation of interventions toward it.

Authors:  Dongmin Guo; King C Li; Timothy R Peters; Beverly M Snively; Katherine A Poehling; Xiaobo Zhou
Journal:  Sci Rep       Date:  2015-03-11       Impact factor: 4.379

10.  Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model.

Authors:  Daniel J Fullen; Nicolas Noulin; Andrew Catchpole; Hosnieh Fathi; Edward J Murray; Alex Mann; Kingsley Eze; Ganesh Balaratnam; Daryl W Borley; Anthony Gilbert; Rob Lambkin-Williams
Journal:  PLoS One       Date:  2016-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.